// App-Quantinova.ai

: Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Researchers

Presenter

  • Sarah Gooding

Principal Investigators

  • Chad C. Bjorklund

  • Michael Amatangelo

  • Yan Ren

  • Mathieu Marella

  • Suzana Couto

  • Christopher Park

  • Sneh Lata

  • Reshma Nibhani

  • Fadi Towfic

  • Udo Oppermann

  • Karthik Ramasamy

  • William E. Pierceall

  • Paresh Vyas

  • Anjan Thakurta

Medical Centers

  • IGF Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Translational Development and Diagnostics, Celgene Corporation, Summit, NJ

  • Exploratory Toxicology, Celgene Corporation, San Diego, CA

  • Celgene Corporation, Summit, NJ

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Pomalidomide

  • CC-4047

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved